- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cellceutix Nears Completion of Phase 2 Trial of New Oral Treatment for Psoriasis
Cellceutix Corporation (OTC: CTIX) announced that approximately 75 percent of the subjects enrolled in its Phase 2 clinical trial of Prurisol for the treatment of chronic plaque psoriasis have completed dosing, defined as 84 days of daily treatments of Prurisol or placebo.
Cellceutix Corporation (OTC: CTIX) announced that approximately 75 percent of the subjects enrolled in its Phase 2 clinical trial of Prurisol for the treatment of chronic plaque psoriasis have completed dosing, defined as 84 days of daily treatments of Prurisol or placebo. The subjects will now be followed for an additional 4 weeks, without taking any further study medication.
According to the company’s press release:
The four-arm multi-center Phase 2 trial, three arms with different dosing regimens of Prurisol and one arm placebo, is designed to assess the efficacy and safety of Prurisol given orally compared to placebo in a randomized, double-blind setting in patients with mild to moderate chronic plaque psoriasis. The trial was expected to enroll 100 subjects and actually enrolled 115 subjects. The primary efficacy endpoint will be the percentage of subjects with greater than or equal to a 2-point improvement in Investigator’s Global Assessment (IGA) rating as defined by visual inspections of patient lesions. The final study visit for the last subject is expected early in April 2016, with top-line data anticipated approximately four weeks later.
Edward Walters, Head of Clinical Operations at Cellceutix commented:
The completion of this study of Prurisol will mark another important milestone for Cellceutix. I am very eager to see the unblinded data, as we structured this trial to give us a broad view of the activity of Prurisol in humans. The goal is to show the compound is safe and effective, while pointing us to an optimal dosing regimen for a late-stage trial. For the good of the millions of people suffering from psoriasis, we hope that Prurisol can one day provide a much-needed option to often-used biologics that are known to have side effects and contraindications, while eventually losing effectiveness in many patients.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.